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Oxidized cell-free hemoglobin (Hb), including covalently cross-linkedHbmultimers, is present in advanced atherosclerotic lesions.
Oxidation of Hb produces methemoglobin (Fe3+) and ferryl hemoglobin (Fe4+ = O2−). Ferryl iron is unstable and can return to
the Fe3+ state by reacting with specific amino acids of the globin chains. In these reactions globin radicals are produced followed
by termination reactions yielding covalently cross-linked Hb multimers. Despite the evanescent nature of the ferryl state, herein
we refer to this oxidized Hb as “ferryl Hb.” Our aim in this work was to study formation and biological effects of ferrylHb. We
demonstrate that ferrylHb, like metHb, can release its heme group, leading to sensitization of endothelial cells (ECs) to oxidant-
mediated killing and to oxidation of low-density lipoprotein (LDL). Furthermore, we observed that both oxidized LDL and lipids
derived from human atherosclerotic lesions trigger Hb oxidation and subsequent production of covalently cross-linked ferrylHb
multimers. Previously we showed that ferrylHb disrupts EC monolayer integrity and induces expression of inflammatory cell
adhesion molecules. Here we show that when exposed to ferrylHb, EC monolayers exhibit increased permeability and enhanced
monocyte adhesion. Taken together, interactions between cell-free Hb and atheroma lipids engage in a vicious cycle, amplifying
oxidation of plaque lipids and Hb. These processes trigger EC activation and cytotoxicity.
1. Introduction
Extracellular lipid accumulation is the main feature of type
IV atherosclerotic lesions.These can progress intomore com-
plicated lesions, in which there is rupture of the fibrous cap
accompanied by either hematoma/hemorrhage and throm-
bus formation or intraplaque hemorrhage in the neovascula-
ture sprouting from the vasa vasorum. These events provoke
the clinical symptoms and are responsible for atherosclerosis-
associated morbidity and mortality [1–5].
Li et al. describe the complicated lesion as a highly oxida-
tive environment containing products of lipid peroxidation
such as lipid hydroperoxides, aldehydes, and carbonyls [6].
The authors suggest that these oxidation products are toxic
for incoming cells, especially macrophages, and constitute
a “death zone,” perhaps explaining the persistence and growth
of atherosclerotic lesions.
Upon plaque rupture or intraplaque hemorrhage, red
blood cells (RBCs) are brought into close contact with plaque
materials. Hemoglobin within RBCs is protected from oxida-
tion because erythrocytes are equipped with highly effective
antioxidant defenses [7]. Based on our previous work, lipids
derived from atheromatous plaque or oxidized low-density
lipoprotein (LDL) can cause RBC lysis and subsequent
oxidation of Hb into metHb [8]. The effect of oxLDL and
plaque lipids can be mimicked by cumene hydroperoxide.
Moreover, enzymatic conversion of lipidhydroperoxides to
alcohol by GSH/GPx causes significant inhibition of RBC
lysis and Hb oxidation triggered by oxLDL and plaque lipids,
suggesting that lipid hydroperoxides play amajor role in these
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processes [8]. We determined the Hb composition of human
complicated atherosclerotic lesions and found that as much
as 50% of the total Hb content is oxidized in these lesions [8].
A complex interplay between Hb and peroxides exists
leading to the formation of metHb (Fe3+), ferrylHb (Fe4+),
and oxoferrylHb (Fe4+ =O2−) species [9, 10]. Protein radicals
are transiently formed in the reactions between the ferryl
or oxoferryl species and the surrounding globin chains with
the involvement of specific amino acids such as 𝛼Tyr-24,
𝛼Tyr-42, 𝛼His-20, 𝛽Tyr-35, 𝛽Tyr-130, and 𝛽Cys-93 [11, 12].
Termination reactions of globin radicals can yield covalently
cross-linkedHbmultimers which are likely to possess unique
biological properties. Previously, we described the presence
of these cross-linkedHb species and elevated dityrosine levels
in human complicated atherosclerotic lesions [8].
Oxidized Hb species have been suggested to act as cyto-
toxic pro oxidants. For example, metHb sensitizes vascular
EC to oxidant-mediated killing [13]. Furthermore when
metHb is present in plasma, it will promote oxidative modifi-
cation of LDL [14]. The release of the prosthetic heme group
is crucial in these metHb-triggered oxidative processes. In
contrast, the pathophysiological effect of the highly oxidized
ferrylHb is less studied, even though its presence in com-
plicated human atherosclerotic lesions has been shown [8].
We have previously shown that ferrylHb, but not native Hb
or metHb, can act as a proinflammatory product targeting
vascular EC [15].
The goal of the present study was to address the potential
interactions between RBC-derived Hb and atheroma lipids,
focusing on the formation and biological effects of ferrylHb.
Here we report that lipids derived from human atheromatous
lesions and oxLDL trigger the formation of covalently cross-
linked Hb multimers, which in turn activate EC. When
exposed to ferrylHb, EC monolayers exhibit increased per-
meability and enhanced monocyte adhesion. These are the
results of amplification of the oxidative reactions betweenHb
and atheroma lipids. Based on these observations, we propose
that lysis of erythrocytes and formation of ferrylHb might
contribute to the progression of atherosclerosis.
2. Materials and Methods
2.1. Materials. Reagents were purchased from Sigma-Aldrich
(St. Louis, MO) unless otherwise specified.
2.2. Tissue Samples. Collection of specimens of human athe-
rosclerotic lesions from beating-heart deceased donors and
extraction of lipids were performed as previously described
[8]. All procedures were approved by the Scientific and
Research Ethics Committee of the Scientific Council of
Health of the Hungarian Government.
2.3. Cell Culture. Human umbilical vein EC (HUVECs) were
removed by exposure to dispase and cultured in medium
199 containing 15% FBS, antibiotics, L-glutamine, sodium
pyruvate, and EC growth factor as described previously [13].
HUVECs were used at passages 2 and 3 within 2 days after-
confluence.
2.4. Hemoglobin Preparation. Hb of different redox states,
that is, (Fe2+) oxyHb, (Fe3+) metHb, and ferrylHb, was pre-
pared as described [15]. Briefly, Hb was isolated from fresh
blood drawn from healthy volunteers using ion-exchange
chromatography on a DEAE Sepharose CL-6B column.
MetHb was generated by incubation (30min, 25∘C) of puri-
fied Hbwith a 1.5-foldmolar excess of K
3
Fe(CN)
6
over heme.
FerrylHb was obtained by incubation (1 h, 37∘C) of Hb with a
10 : 1 ratio of H
2
O
2
to heme. After oxidation, bothmetHb and
ferrylHb were dialyzed against saline (3 times for 3 hours at
4∘C) and concentrated using Amicon Ultra centrifugal filter
tubes (10,000 MWCO, Millipore Corp., Billerica, MA, USA).
Aliquots were snap-frozen in liquid nitrogen and stored at
−80∘C until use. Purity of each Hb preparation was evaluated
by SDS-PAGE followed by staining with ProteoSilver Plus
Silver Staining Kit. The purity of Hb preparations was above
99.9%. Hb concentrations were calculated as described by
Winterbourn [16].
2.5. Preparation and Oxidation of Low-Density Lipoprotein.
LDL was isolated from the plasma of EDTA-anticoagulated
venous blood of healthy volunteers by gradient ultracentrifu-
gation (Beckman Coulter, Inc., Brea, CA, USA). The density
of plasma was adjusted to 1.3 g/mL with KBr and a two-
layer gradient was made in a Quick-Seal ultracentrifuge tube
by layering saline on 10mL plasma. Ultracentrifugation was
performed at 302,000 g for 2 hours at 4∘C (VTi 50.2 rotor).
LDL samples were kept at −70∘C until use and the protein
concentration was determined by Pierce BCA protein assay
Kit (Pierce Biotechnology, Rockford, IL, USA). Oxidation of
LDL was carried out by the addition of heme (5 𝜇mol/L) and
H
2
O
2
(75𝜇mol/L) as in our previous studies. In experiments
assessing the LDL oxidizing potential of different Hb species
EDTA-plasma was incubated for 1 hour at 37∘Cwith different
Hb species, that is, Hb, metHb, and ferrylHb, at a dose of
100 𝜇mol/L of Hb monomer prior to separation of LDL.
2.6. Measurement of Lipid Peroxidation Products in LDL. The
spontaneous oxidation of LDL treated as described previously
was measured over a period of two-week incubation at 4∘C
by measuring the concentrations of conjugated dienes, lipid
hydroperoxides, and thiobarbituric-acid reactive substances
(TBARs). To assess conjugated diene content, LDL samples
were diluted to 200𝜇g protein/mL and optical density was
measured at 234 nm. The method of Wolf was used to mea-
sure the total lipid hydroperoxide content in the LDL samples
[14]. To measure TBARs, 50 𝜇L of a 200𝜇g protein/mL
LDL sample was mixed with 100 𝜇L of thiobarbituric acid
reagent (0.375 g 2-thiobarbituric acid, 2.08mL HCl, 15mL
10% trichloroacetic acid to a final volume of 100mL). After
heating at 90∘C for 20 minutes, the samples were cooled
and extracted with 200𝜇L n-butanol. The upper phase was
measured spectrophotometrically at 532 nm. Results were
calculated using a molar extinction coefficient of 1.56 ×
105M−1 cm−1 and are expressed as nmol TBARs/mg protein.
2.7. Lipid-Mediated Oxidation of Hb. Purified Hb (20𝜇mol/L
heme) was incubated with H
2
O
2
(200𝜇mol/L), native or
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oxidized LDL (50–500𝜇g protein/mL), or lipid derived from
atheromatous lesion (LP) (500 𝜇g lipid/mL). Changes in Hb
redox state were followed by UV-visible spectra recorded on
a Beckman DU-800 spectrophotometer.
2.8. EC Cytotoxicity Assay. Confluent HUVECs grown in
96-well tissue-culture plates were washed twice with PBS
and exposed to heme and different Hb species, that is, Hb,
metHb, or ferrylHb (10 𝜇mol/L heme) in HBSS. After 1 hour
of incubation cells were washed and treated with H
2
O
2
(75 𝜇mol/L) for 3 hours. Cell viability was assessed by MTT
assay as described previously [17]. In separate experiments
HUVECs were exposed to LDL (250𝜇g protein/mL) which
was treated with heme and different Hb species, that is,
Hb, metHb, or ferrylHb (10 𝜇mol/L heme). Cell viability was
measured by MTT assay after 6 hours of LDL exposure.
2.9. EC Monolayer Permeability Assay. HUVECs were cul-
tured on gelatin-coated hanging cell culture inserts (Mil-
lipore Corporation, Billerica, MA, USA). After reaching
confluence, cells were treated with heme, Hb, metHb, or
ferrylHb (10 𝜇mol/L heme) for 12 hours. After treatment,
fluorescein sodium salt (1𝜇mol/L) in complete medium was
added to the apical filter compartment, followed by a 60-
minute incubation. Samples were collected from the lower
basolateral compartment and fluorescence was measured by
a fluorescence microplate reader at 488/525 nm (Synergy4,
BioTek, Winooski, USA).
2.10. Monocyte Adhesion Assay. HUVECs were cultured on
cover slips in 24-well plates and treated with heme, Hb,
metHb, and ferrylHb (10 𝜇mol/L heme) for 12 hours. Periph-
eral blood mononuclear cells (PBMCs) were prepared by
using Histopaque-1077. CD14 positive cells were then sep-
arated using a magnetic isolation procedure (MACS CD14
microbeads, Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany).Monocyteswere suspended in serum-freeDMEM
to a concentration of 5 × 106 cells/mL and incubated with
Calcein AM (5 𝜇mol/L) for 30 minutes at 37∘C. The labeled
monocytes (105 cells/well) were added to HUVECs in com-
plete culture medium and incubated for 30 minutes at 37∘C,
followed by two washes with Ca2+- and Mg2+-containing
HBSS to remove nonadherent cells. Cells were fixed with
paraformaldehyde (3.7%, Merck) and blocked with donkey
serum (5%, Jackson ImmunoResearch Europe Ltd., Suffolk,
UK) for 30 minutes. After blocking, cells were stained with
TRITC-conjugated phalloidin (25 𝜇g/mL) and with Hoechst
(0.5 𝜇g/mL). Images were taken with a fluorescent micro-
scope at a magnification of 400x (DM2500, Leica Microsys-
tems GmbH, Wetzlar, Germany).
2.11. Quantitative Real-Time PCR (qRT-PCR). Confluent
HUVECs grown in 6-well plates were exposed to heme
and different Hb species, that is, Hb, metHb, and ferrylHb
(100 𝜇mol/L heme) in complete medium. After a 6-hour
treatment cells were washed and total RNA was isolated
using RNAzol STAT-60 according to the manufacturer’s
instructions (TEL-TEST Inc., Friendswood, TX,USA). Levels
of heme oxygenase-1 (HO-1) and cyclophilin mRNA were
measured by real-timeRT-PCR. RNAwas reverse transcribed
by using Superscript II reverse-transcriptase (Invitrogen,
Life Technologies Co., Carlsbad, CA, USA). Real-time
PCR was carried out using the iCycler iQ Real-Time PCR
System (Bio-Rad Laboratories, Hercules, CA, USA). The
25 𝜇L reaction mixture contained 0.3 nmol/L primers (for
HO-1: + GGT-GAT-AGA-AGA-GGC-CAA-GAC-TG and −
GGT-GTC-ATG-GGT-CAG-CAG-CT, for cyclophilin +
ACG-GCG-AGC-CCT-TGG and − TTT-CTG-CTG-TCT-
TTG-GGA-CCT), 0.13 nmol/L fluorescent probes (for HO-1
CTC-AAC-ATC-CAG-CTC-TTT-GAG-GAG-TTG-CAG,
for cyclophilin CGC-GTC-TCC-TTT-GAG-CTG-TTT-
GCA), 3mmol/L MgCl
2
, 0.2mmol/L dNTPs and 0.05U/mL
Taq DNA polymerase (Invitrogen, Life Technologies Corp.,
Carlsbad, CA, USA). Results are expressed as fold increase
in HO-1/cyclophilin gene expression ratio compared to that
of untreated cells.
2.12. Western Blot. HUVECs were cultured in 6-well plates
and exposed to heme and different Hb species, that is, Hb,
metHb, or ferrylHb (100𝜇mol/L heme) in complete medium.
After 8 hours of incubation the cells were solubilized in
10mmol/LTrisHCl, containing 5mmol/LEDTA, 150mmol/L
NaCl (pH 7.2), 1% Triton X-100, 0.5% Nonidet P-40, and
protease inhibitors (Complete Mini, F. Hoffmann-La Roche
Ltd., Basel, Switzerland). Proteins (20𝜇g) were applied to
12.5% SDS-PAGE gels. After electrophoresis, proteins were
transferred to a nitrocellulose membrane (Amersham Bio-
sciences Corp., Piscataway, NJ, USA) andHO-1was identified
using a mouse anti-human HO-1 monoclonal antibody (Cat
no. 374087, Calbiochem,MerckKGaA,Darmstadt, Germany)
at a dilution of 1 : 2500. To ascertain equivalent protein load-
ing, membranes were stripped and reprobed with a mouse
anti-human GAPDH antibody (Cat no. N13300-221, Novus
Biologicals, LLC, Littleton, CO, USA) at a dilution of 1 : 1000.
To detect ferritins, samples were subjected to native gel
electrophoresis. Anti-human ferritinH and L antibodies were
a generous gift from Paolo Arosio. Primary antibodies were
detected by using horseradish peroxidase-conjugated donkey
anti-rabbit or goat anti-mouse IgG secondary antibodies.
Antigen-antibody complex was detected by a horseradish
peroxidase chemiluminescence system according to theman-
ufacturer’s instructions (Amersham Biosciences Corp., Pis-
cataway,NJ,USA).Quantificationwas performed using video
densitometry (AlphaDigiDoc RT, Alpha Innotech Corp., San
Leandro, CA, USA).
2.13. Detection of Covalently Cross-Linked Hb Multimers. Hb
samples (1–4𝜇g) were applied to 12.5% SDS-PAGE gels. After
electrophoresis, proteins were transferred to a nitrocellulose
membrane (Amersham Biosciences Corp., Piscataway, NJ,
USA) and Hb was identified using a HRP-conjugated goat
anti-human Hb polyclonal antibody (Cat no. ab19362-1,
Abcam Plc., Cambridge, UK) at a dilution of 1 : 15000. In
other cases cross-linkedHbmultimerswere detected by silver
staining following SDS-PAGE.
2.14. Statistical Analysis. Data are shown as mean ± S.D. Sta-
tistical analysis was performed by one-way ANOVA or
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Student’s t-test as appropriate. 𝑃 < 0.05 was considered sig-
nificant.
3. Results
3.1. Oxidized Hemoglobin Species Induce Oxidative Modi-
fication of LDL. To model the possible interactions that
could take place inside a complicated atherosclerotic lesion
between lipids and different Hb species, we purified Hb from
human blood and generatedmetHb and ferrylHb.We should
note that ferrylHb is not a homogenous chemical entity
but is a mixture of globin- and porphyrin-centered radicals
(which can be very short-lived) and covalently cross-linked
Hb multimers. Human EDTA-anticoagulated plasma was
incubated with heme and the three different Hb species, that
is, Hb, metHb, and ferrylHb (100 𝜇mol/L heme). After 1 hour
of incubation at 37∘C LDLwas isolated by ultracentrifugation
and oxidative modification of LDL was monitored by the
formation of conjugated dienes, lipid hydroperoxides, and
TBARs in samples incubated at 4∘C for 15 days. Lipid peroxi-
dation did not occur in LDL samples derived fromnontreated
or Hb-treated plasma samples (Figures 1(a)–1(c)). Starting on
day 2 following-isolation, heme treatment caused extensive
and rapid increase in conjugated dienes, LOOH, and TBARs
content of LDL (Figures 1(a)–1(c)). MetHb, and ferrylHb
also initiated oxidative modification of LDL and increased
the levels of lipid peroxidation products at days 7–10 after
isolation (Figures 1(a)–1(c)).The kinetics of formation of lipid
peroxidation products in the LDL was strictly dependent on
the dose of ferrylHb (Figures 1(d)–1(f)).
Heme released from oxidized Hb in plasma preferentially
associates with LDL and is degraded shortly thereafter in
the course of lipid peroxidation [14]. Therefore we assessed
whether the heme moiety of ferrylHb is released and eventu-
ally taken up by LDL and degraded during lipid peroxidation.
Plasma was incubated with heme or ferrylHb for 1 hour
at 37∘C followed by LDL separation and measurement of
LDL-associated heme. As shown in Figure 1, ferrylHb treat-
ment dose-dependently increased the concentration of LDL-
associated heme in the LDL (Figure 1(g)).
In order to determine whether similar events occurred
in whole plasma, we treated fresh plasma with heme, Hb,
metHb, or ferrylHb. Following the isolation of LDL, the
concentration of LDL-associated heme was measured on the
day of LDL isolation and 15 days later. We observed that
LDL-associated heme underwent degradation when plasma
was treated with heme, metHb, or ferrylHb (Figure 1(h)). In
contrast the heme content of LDL derived from Hb-treated
plasma did not change over a 15-day incubation period
(Figure 1(h)).These results suggest that ferrylHb, like metHb,
readily releases heme, following which iron is released upon
oxidative scission of heme and serves to catalyze the process
of lipid peroxidation.
3.2. Oxidized Hb Species Trigger EC Death. We have shown
previously that heme and metHb make EC more sensitive
to oxidative stress by delivering redox active iron, and thus
amplifying the generation of reactive oxygen species [13].
Therefore we tested whether ferrylHb, similar to metHb, can
sensitize EC to oxidative stress. Confluent HUVECs were
pretreated with heme, Hb, metHb, or ferrylHb at a dose of
5 𝜇mol/L heme. After 1 hour, heme-containing solutions were
removed and cells were challenged with H
2
O
2
(75𝜇mol/L).
Neither heme nor hemoglobins or H
2
O
2
alone caused EC
death. Moreover, no cytotoxicity was observed when Hb-
treated cells were exposed to H
2
O
2
. In contrast, when
HUVECs were pretreated with heme, metHb, or ferrylHb
prior to H
2
O
2
exposure, cell viability decreased (Figure 2(a)).
This shows that while not cytotoxic per se, heme, metHb, and
ferrylHb sensitize EC to H
2
O
2
-driven cytotoxicity.
In our previous work we demonstrated that heme and
metHb can exert cytotoxic effects on EC via oxidative mod-
ification of LDL [14]. To assess whether this is also the case
with ferrylHb, LDL was incubated with heme, Hb, metHb,
or ferrylHb (10 𝜇mol/L heme) overnight, and the resulting
LDL was tested for cytotoxic effects. We observed that LDL
samples treated with heme, metHb and ferrylHb became
highly toxic to HUVECs (Figure 2(b)). In contrast, Hb did
not generate cytotoxic LDL (Figure 2(b)).
3.3. Oxidized Hemoglobin Species Induce HO-1 and Ferritin
Expression in HUVECs. Upon exposure to free heme, EC
upregulate the expression of HO-1 and H-ferritin to assure
degradation of heme and safe storage of liberated iron,
respectively. We have previously demonstrated that native
(oxy) Hb does not induce HO-1 and ferritin in EC, whereas
metHb does, because it releases its heme moiety [13]. We
asked whether ferrylHb could transfer heme groups to the
endothelium and thus upregulateHO-1 and ferritin synthesis.
We observed that ferrylHb, similar to metHb, induces HO-
1 mRNA and protein expression (Figures 3(a) and 3(b)). As
with HO-1 expression, ferritin level was also increased in
ferrylHb-treated cells compared to vehicle-treated controls
(Figure 3(c)). These effects occur in a dose-dependent man-
ner. However, when compared at a heme-molar ratio the
effect of ferrylHb is lower than that of free heme (Figures 3(d)
and 3(e)).
3.4. OxLDL and Reactive Lipid Mediators Derived from Com-
plicated Atherosclerotic Lesions Initiate Hb Oxidation and
Globin-Globin Crosslinking. Lipid hydroperoxides, such as
those found in oxLDL as well as in lipids derived from athero-
matous lesions, can initiate Hb oxidation resulting in metHb
formation and subsequent heme release [17]. Oxidized lipids
and ferrylHb coexist in advanced atherosclerotic lesions but
the role of reactive lipid mediators in the formation of
ferrylHb and the subsequent crosslinking of Hb subunits
has not been addressed. Therefore, we tested native and
oxidized LDL, as well as lipids derived from human type
IV atherosclerotic lesions, for their ability to induce Hb
crosslinking, a surrogate marker of ferrylHb formation. Hb
(20𝜇mol/L heme) was treated with H
2
O
2
(200𝜇mol/L),
native or oxidized LDL (500𝜇g protein/mL), or lipids derived
from human type IV atherosclerotic lesions (LP) (500 𝜇g
lipid/mL). After a 2-hour incubation at 37∘C, samples (4 𝜇g
protein/lane) were subjected to SDS-PAGE followed by sil-
ver staining. Covalently cross-linked Hb dimer formation
was observed in H
2
O
2
-treated as well as in oxLDL- and
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Figure 1: FerrylHb triggers oxidative modification of LDL. Human plasma was incubated with heme, Hb, metHb, and ferrylHb for 1 hour at
37∘C, followed by separation of LDL. Concentrations are indicated and expressed as 𝜇mol/L heme groups. Following separation samples were
kept at 4∘C. Conjugated dienes ((a) and (d)), LOOH ((b) and (e)), and TBARs ((c) and (f)) in LDL samples were measured every day for 15
days. Results are representative of 3 independent experiments. Heme contents of the same samples were measured on the day of separation
(g) and 15 days later (h). Data represent mean ± S.D. of 3 independent experiments.
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Figure 2: FerrylHb triggers EC death via different mechanisms. (a) Confluent HUVECs grown on 96-well plates were exposed to heme, Hb,
metHb, and ferrylHb (5𝜇mol/L heme) in HBSS for 1 hour. After washing with HBSS, cells were challenged with H
2
O
2
(75 𝜇mol/L in HBSS)
for 4 hours, followed by MTT assay to assess cell viability. (b) LDL was incubated with heme, Hb, metHb, and ferrylHb (10 𝜇mol/L heme)
overnight. HUVECs were exposed to LDL samples at a dose of 250𝜇g protein/mL for 4 hours. MTT assay was performed to determine cell
viability. Results are shown as mean ± S.D. (𝑛 = 4) from one representative experiment of three.
plaque lipid-treated Hb samples (Figure 4(a)). In contrast,
native LDL did not induce Hb crosslinking (Figure 4(a)).
Oxidation state of iron in the Hb modified by oxLDL
was determined spectrophotometrically. OxLDL increased
in a dose-dependent manner the percentage of Fe3+ Hb
as assessed by an increased absorbance at 𝜆 = 630 nm
accompanied by a decrease at 𝜆 = 577 nm and 𝜆 = 562 nm
(Figures 4(b) and 4(c)). With increasing doses of oxLDL,
dimer formation became more prevalent and at higher doses
tetrameric and multimeric ferrylHb formation occurred as
well (Figure 4(d)).
3.5. Hb Oxidation and Crosslinking Induced by H
2
O
2
and
Reactive Lipid Mediators Can Be Inhibited by Haptoglobin
(Hp) or GSH/GPx. Cell-freeHb binds to the acute-phase pla-
sma protein Hp, promoting its endocytosis via the Hp recep-
tor CD163, and thus preventing Hb accumulation in plasma
[18, 19]. We tested whether binding of Hb to Hp inhibits
ferrylHb formation. Hb oxidation was induced with H
2
O
2
or
oxLDL in the presence or absence of Hp. After 90 minutes
Fe3+-heme content was determined spectrophotometrically
(Figure 5(a)), and covalently cross-linked Hb formation was
assessed by western blotting (Figure 5(b)). Hp slightly inhib-
ited H
2
O
2
-mediated metHb formation. A more pronounced
inhibitory effect of Hp was seen on Hb crosslinking; Hp
inhibited by 42% and 60% covalently cross-linked Hb dimer
formation in response to H
2
O
2
and oxLDL, respectively.
These results suggest that Hp has a role in suppressing the loss
of Hb heme/iron and preventing the formation of covalently
cross-linked Hb species.
Lipid hydroperoxides in the oxLDL can trigger Hb oxida-
tion, resulting in the formation of metHb [17], but the role of
lipid hydroperoxides in Hb crosslinking has not been tested.
To examine whether lipid hydroperoxides in oxLDL are
responsible for oxLDL-mediated Hb crosslinking, we used
glutathione-glutathione peroxidase (GSH/GPx) to decom-
pose H
2
O
2
and lipid hydroperoxides and assessed their effect
on Hb crosslinking. GSH/GPx reduced the formation of
metHb by 93% when Hb was oxidized by H
2
O
2
, and by 70%
when Hb was exposed to oxLDL (Figure 5(a)). Exposing Hb
toH
2
O
2
or oxLDL in the presence ofGSH/GPx led to 90–95%
less dimer formation compared to Hb exposed to H
2
O
2
or
oxLDL in the absence of GSH/GPx (Figure 5(b)). These data
highlight the critical role of lipid hydroperoxides inmediating
Hb oxidation and subsequent covalent crosslinking of the Hb
subunits.
3.6. FerrylHb Increases EC Monolayer Permeability and
Enhances Monocyte Adhesion. We have previously demon-
strated that ferrylHb activates EC in vitro, leading to the
formation of intercellular gaps disrupting the endothelial
monolayer [15]. Here we show that this effect is dose depen-
dent (Figure 6(a)) and that intercellular gap formation is
associated functionally with increased endothelial monolayer
permeability (Figure 6(b)). This is a unique feature of fer-
rylHb as neither Hb nor metHb increased EC monolayer
permeability. In our previous work we also showed that
ferrylHb induces the expression of proinflammatory genes
in EC [15]. Therefore we asked whether ferrylHb-triggered
induction of these proteins—known to play a role in cell
adhesion—is accompanied by increased monocyte adhesion
to vascular EC. We found that human monocytes readily
adhered to ferrylHb-treated EC. In contrast, treatment of
EC with heme, Hb, or metHb did not promote monocyte
adhesion (Figure 6(c)).These data suggest that the formation
of ferrylHb may be a crucial event in the promotion of
inflammatory responses.
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Figure 3: FerrylHb induces HO-1 and ferritin in EC. Confluent HUVECs grown on 6-well plates were exposed to heme, Hb, metHb, and
ferrylHb (100𝜇mol/L heme or as indicated in complete medium containing 15% of FBS). After 4 hours of incubation total RNA was isolated
and HO-1 mRNA level was measured by quantitative RT-PCR (panels (a) and (d)). For protein expression, HUVECs were solubilized after
8 hours of treatment. HO-1 and ferritin H and L expression was detected by Western blot ((b) and (e)) or with ELISA (c). Immunoblots
were reprobed with GAPDH and are representative of three independent experiments. Results are shown as mean ± S.D. (𝑛 = 3) from one
representative experiment of three.
4. Discussion
The abundance of antioxidant enzymes andmolecules makes
the erythrocyte a relatively protective environment for Hb.
Preventing or reversing Hb oxidation in RBCs is crucial.
Under normal conditions, senescent RBCs are removed
from the circulation by hemophagocytic macrophages of the
reticuloendothelial system in a well-regulated way. Several
pathological conditions are associatedwith intra- or extravas-
cular release ofHb and subsequent increase of oxidative stress
[20, 21].
Hb oxidation leads to the formation of different Hb
oxidation products, including ferryl iron containing heme,
globin- and heme-centered radicals, covalently cross-linked
heme-globin species and covalently cross-linked globin-
globin multimers. In the literature these oxidized Hb species,
are called, as a group, “ferrylHb.” These can be found in
human blood under normal [22, 23] or pathological con-
ditions [24]. We have previously reported the presence of
covalently cross-linked globin-globin multimers of ferrylHb
in human atherosclerotic lesions [8], but the involvement of
8 Oxidative Medicine and Cellular Longevity
Hb
H2O2 nLDL oxLDL LP
Dimer
Monomer
Tetramer
−
(a)
500 550 600 650 700
O
pt
ic
al
 d
en
sit
y
Wavelength (nm)
Hb
metHb
Hb + oxLDL (50 𝜇g/mL)
Hb + oxLDL (100 𝜇g/mL)
Hb + oxLDL (200 𝜇g/mL)
Hb + oxLDL (400 𝜇g/mL)
0.05
0.15
0.25
0.35
0.45
(b)
0
20
40
60
80
100
120
D
ist
rib
ut
io
n 
of
 h
em
e-
Fe
2
+
an
d 
Fe
3
+
(%
 o
f t
ot
al
 h
em
e)
Heme-Fe2+
Heme-Fe3+
+ + + + +
− 50 100 200 400
Hb
oxLDL (𝜇g/mL)
𝑃
<
0
.0
1
𝑃
<
0
.0
0
1
𝑃
<
0
.0
1
𝑃
<
0
.0
1
𝑃
<
0
.0
1
𝑃
<
0
.0
0
1
𝑃
<
0
.0
0
1
𝑃
<
0
.0
0
1
(c)
Hb ferrylHb
Hb + oxLDL
50 100 200 400 (𝜇g/mL)
Dimer
Monomer
Tetramer
(d)
Figure 4: Oxidized LDL and atheroma lipids cause Hb oxidation and formation of ferrylHb. (a) Human Hb (20 𝜇mol/L heme) was
treated with H
2
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(200𝜇mol/L), native LDL (400𝜇g/mL), oxLDL (400𝜇g/mL), and lipid derived from human atherosclerostic plaque (LP)
(400𝜇g/mL). After 90 minutes of incubation Hb samples (4𝜇g/lane) were subjected to SDS-PAGE followed by silver staining. ((b), (c),
and (d)) Human Hb was incubated with oxLDL (50–400𝜇g/mL) for 90 minutes. ((b) and (c)) Spectral scan of Hb samples were taken and
concentrations of Hb and metHb were calculated based on the visible spectra. (d) Hb samples (4𝜇g/lane) were subjected to SDS-PAGE
followed by silver staining. Silver staining images and spectral scan are representatives of three independent experiments. Results are shown
as mean ± S.D. (𝑛 = 3) from one representative experiment of three.
ferrylHb in the pathogenesis of atherosclerosis remains to be
further defined.
Subendothelial retention of excess circulating LDL, oxi-
dation of the trapped LDL, and immunological responses
triggered by oxLDL are widely regarded as elements of
atherogenesis (reviewed in [25]). Oxidation-specific epitopes
are present on oxidized LDL particles, apoptotic cells and
modified proteins in the vessel wall. It has been shown that
elevated concentration of these epitopes predicts myocardial
infarction, stroke and cardiovascular death [26]. Consid-
ering this close relationship between disease outcome and
oxidative modifications it is highly important to characterize
the potential oxidizing agents in the vessel wall. Hb can
be a strong candidate that triggers oxidative damage in the
atherosclerotic plaque.
The two mechanisms via which Hb can enter to the
atherosclerotic plaque area are (i) plaque rupture or (ii)
intraplaque hemorrhage; the latter is common in advanced
coronary atherosclerotic lesions [27–29]. Intraplaque hem-
orrhage is most likely originated from immature neoves-
sels invading the atherosclerotic plaques as a result of its
angiogenic activity [30, 31]. Recently, intraplaque hemorrhage
has been linked to plaque vulnerability and considered as
a critical event in triggering atherosclerosis-associated acute
clinical symptoms [32].
Following intraplaque hemorrhage erythrocyte mem-
brane proteins and iron accumulate in the plaque, suggesting
that RBCs entering atherosclerotic plaques are lysed, their
Hb is oxidized, and heme is released and degraded [4].
We have previously shown that both lipids extracted from
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Figure 5: GSH/GPx and Hp inhibit H
2
O
2
and oxLDL-mediated oxidation and crosslinking of Hb. ((a) and (b)) Human Hb (20𝜇mol/L
heme) was pretreated with Hp (50𝜇mol/L) for 10 minutes at 37∘C followed by 90 minute incubation with H
2
O
2
(200𝜇mol/L) and oxLDL
(400𝜇g/mL). Separately, H
2
O
2
(200𝜇mol/L) and oxLDL (400𝜇g/mL) were pretreated with GSH/GPx for 10 minutes at 37∘C followed by
a 90-minutes of incubation with Hb (20𝜇mol/L heme). (a) MetHb was determined spectrophotometrically. (b) Oxidation-induced dimer
formation was monitored by Western blot. Immunoblot is a representative of three independent experiments. Results are shown as mean ±
S.D. (𝑛 = 3) from one representative experiment of three.
human atheromatous plaques and oxidized LDL cause lysis
of RBCs and subsequent Hb oxidation [8]. Theoretically
these oxidized Hb species can initiate LDL modification via
two distinct mechanisms with the involvement of (i) globin
radicals or (ii) heme iron. For example, in a reaction system
containing Hb, H
2
O
2
, and LDL, lipid peroxidation is rapid
leading to the formation of conjugated dienes in less than
1 hour in the presence of 200𝜇g/mL LDL, 3mmol/L heme,
and 4.5mmol/L H
2
O
2
[33]. This reaction has been shown
to be triggered by globin radicals produced in the reaction
of Hb and H
2
O
2
[33]. On the other hand, heme release
from oxidized Hb can also contribute to LDL oxidation. This
notion is supported by the facts that (i) heme itself is a potent
inducer of LDL oxidation, (ii) metHb, that does not have
radical properties but releases heme moieties and initiates
LDL oxidation and (iii) heme and Hb-initiated oxidation of
LDL is inhibited by the heme-binding protein, hemopexin
[34, 35]. In parallel with previously reported findings [33]
here we demonstrated that ferrylHb can trigger LDL oxida-
tion. We showed that heme derived from ferrylHb has been
associated with LDL and caused a slow lipid peroxidation
in 12 days in the presence of 1mg/mL LDL and ≈50𝜇mol/L
heme (Figure 1). During this period of time LDL-associated
ferrylHb-derived heme underwent degradation similar to
that of heme which is degraded during heme-mediated LDL
oxidation. These results suggest that ferrylHb, depending on
the circumstances of its production and the environment, can
initiate LDL oxidation via two distinct mechanisms in which
globin radicals and heme play the major roles.
Hydrogen peroxide is the most studied reactive oxygen
metabolite that can induce oxidation of Hb in cell-free
systems [36, 37], as well as in intact erythrocytes [38]. In these
complex reactions different Hb species are formed, including
metHb and ferrylHb [9, 10]. Ferryl iron is unstable and
reacts with specific amino acids of the surrounding globin
chains [11, 12] resulting in the formation of globin radicals.
Subsequent reactions between globin radicals yield covalently
cross-linked Hb multimers [39]. Besides classical reactive
oxygen metabolites, organic peroxides were shown to induce
the leakage of Hb fromhuman erythrocytes [40] and the gen-
eration of metHb [41]. FerrylHb generation was detected in
the interaction between ruptured erythrocytes and LDL [42,
43]. Parallel with these findings here we showed that oxLDL
but not native LDL caused Hb oxidation and subsequent
covalent crosslinking of Hb subunits (Figure 4.) We found
that formation of crosslinked Hb species is dose dependent,
in a way that higher doses of oxLDL result in the formation
of larger multimers with higher molecular weights.We found
that pretreatment of oxLDL with GSH/GPx that converts
lipid hydroperoxide to alcohol inhibited Hb oxidation and
concomitant crosslinking suggesting the involvement of lipid
hydroperoxides in the generation of these species (Figure 5).
In case of intravascular or extravascular hemolysis or
hemorrhage the deleterious effects of cell-freeHb are thought
to be controlled mainly via the action of Hp [44], that
binds to Hb with high affinity [18, 45] and promotes its
clearance by monocytes and resident macrophages of the
reticuloendothelial system via scavenger receptor CD163
[19]. CD163-mediated endocytosis of Hp-Hb complex is
followed by rapid induction of HO-1 that degrades heme
into CO, biliverdin, and iron [21]. Concomitant with HO-1
induction, ferritin is upregulated to store the iron released
from heme [19, 46]. Colocalized expression of CD163 and
HO-1 was reported in a subpopulation of macrophages in
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Figure 6: FerrylHb disrupts endothelial monolayer and induces leukocyte adhesion in HUVECs. (a) Confluent HUVECs grown in 6-well
plates were exposed to Hb and ferrylHb at a dose of 0–20 𝜇g/mL overnight. Images are 100X, taken with an inverted microscope (Carl
Zeiss 426126), and analyzed by ImageJ software. (b) Confluent HUVECs grown in hanging cell culture inserts were treated with heme, Hb,
metHb, and ferrylHb (10 𝜇mol/L heme groups each) for 12 hours. Fluorescein (1 𝜇mol/L) was added into the apical filter compartment and
was detected in the lower compartment after a 60-minute incubation. Endothelial permeability is expressed as fold increase over nontreated
cells. (c) Confluent HUVECs were treated with heme, Hb, metHb, and ferrylHb (10𝜇mol/L heme) for 12 hours. Monocytes were labeled and
added to HUVECs (105 cells/well) for 30 minutes at 37∘C. Cells were stained with TRITC-conjugated phalloidin and with Hoechst. Images
are 400x. Results are shown as mean ± S.D. (𝑛 = 3) from one representative experiment of three. Images are representative of 3 independent
experiments.
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neovascularized atherosclerotic lesions [46], as well as in
lesions with intraplaque hemorrhage [47]. This macrophage
subpopulation degrades Hb more quickly and produces less
reactive oxygen species and more of the anti-inflammatory
cytokine IL-10. Based on these features this hemorrhage-
associatedmacrophage subpopulationwas suggested to act in
an anti-inflammatory and atheroprotective manner [46, 48].
Recently it has been shown that oxidative crosslinking
of Hb is associated with reduced Hp binding; therefore, the
endogenous Hp-CD163 scavenger pathway is impaired [39].
As a result of inadequate uptake of these structurally altered
Hb species, macrophages fail to induceHO-1, a stress respon-
sive enzyme that provides the anti-inflammatory and athero-
protective effects of hemorrhage-associatedmacrophages [39,
48]. Also, impaired uptake of ferrylHb might result in the
release of free heme which induces programmed necrosis or
apoptosis of macrophages [49] as well as other cells [50].
Besides facilitating the removal of cell-free Hb from
circulation, Hp has been shown to prevent Hb oxidation as
well as heme loss from oxidized Hb [33, 51, 52]. Cooper et
al. explored the mechanism underlying the protective effect
of Hp in peroxide-mediated Hb oxidation. Interestingly, they
found that in the presence of Hp the steady-state concen-
tration of ferryl iron increases, while lipid peroxidation is
inhibited. This is because Hp binding stabilizes the ferryl
iron as well as the globin radical located on tyrosine 145
[53]. In agreement with these findings we reported here
that oxLDL-mediated Hb oxidation and formation of cova-
lently crosslinked Hbmultimers are inhibited by haptoglobin
(Figure 5).
EC activation and damage are associated with the ini-
tiation and progression of atherosclerosis [54]. Oxidation
of Hb can harm endothelial cells in different ways. Heme
released upon Hb oxidation can sensitize EC to oxidant-
mediated killing [13] and can induce EC death via triggering
oxidativemodification of LDL [14, 55]. Herewe demonstrated
that ferrylHb exerts cytotoxic effect towards the vascular
endothelium, mainly, via inducing oxidative modification of
LDL, as ferrylHb slightly sensitizes EC to H
2
O
2
-mediated
killing. Heme release is crucial in cellular responses triggered
by metHb. When challenged with metHb, EC upregulate
HO-1 to catabolize heme and ferritin to store liberated iron
in a redox inactive form. We found that ferrylHb, similar
to metHb, induces HO-1 and ferritin expression in EC.
This suggests that heme release is not impaired by covalent
crosslinking of globin chains in ferrylHb. Recentlywe showed
that Hb oxidation via the generation of ferrylHb exerted
proinflammatory effects on vascular EC [15]. In response
to ferrylHb, EC rearrange their actin cytoskeleton leading
to intercellular gap formation [15]. FerrylHb induces the
expression of proinflammatory genes, for example, E-selectin,
Icam-1, andVcam-1 in EC [15].Herewe demonstrated that gap
formation is associatedwith increased endothelial permeabil-
ity, and that elevated expression of adhesion molecules led
to increased number of adherent monocytes on the surface
of EC (Figure 6). Free heme and metHb do not activate
EC, suggesting that heme release does not play a role in
the ferrylHb-mediated inflammatory response. Furthermore
Hb is also unable to induce EC, suggesting that the cross-
linked species of ferrylHb act as an important and unique
proinflammatory agonist.
5. Conclusion
In conclusion, we demonstrated that ferrylHb containing
covalently cross-liked Hb multimers can be formed in
atherosclerotic lesions by the interactions of Hb and reactive
lipid components,mainly lipid hydroperoxides, in the plaque.
There are similarities and differences between metHb and
ferrylHb. Both Hb oxidation products can release heme,
sensitizing EC to oxidant-mediated killing and initiating lipid
peroxidation of LDL. On the other hand, FerrylHb is unique
in that it acts as a proinflammatory agonist by targeting
vascular EC. This activation results in increased EC mono-
layer permeability and enhanced monocyte adhesion. Taken
together, interactions between cell-free Hb and atheroma
lipids provoke a vicious cycle promoting the oxidation of
plaque lipids and Hb which in turn trigger endothelial acti-
vation and cytotoxicity.
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